trending Market Intelligence /marketintelligence/en/news-insights/trending/_O48VAUnJT_NPqh1DkKtzw2 content esgSubNav
In This List

La Jolla's drug for low blood pressure wins FDA approval

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


La Jolla's drug for low blood pressure wins FDA approval

The U.S. Food and Drug Administration approved La Jolla Pharmaceutical Co.'s Giapreza to increase blood pressure in adults with septic or other distributive shock.

The agency advised that the drug can cause dangerous blood clots with serious consequences, and preventive treatment for blood clots should be used.

Shock is a life-threatening condition that occurs due to lack of blood flow and can result in organ failure and death.

La Jolla plans to make the drug available for patients in the U.S. in March 2018.